Using intravenous BCG to prevent tuberculosis in SIV-infected macaques
Preventing TB with intravenous BCG in SIV-infected macaques
['FUNDING_R01'] · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · NIH-11059888
This study is looking at whether giving the BCG vaccine through an IV can help protect macaques with a virus similar to HIV from tuberculosis, which is a big health concern for people with weakened immune systems, and the goal is to find better ways to prevent TB in people living with HIV.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF PITTSBURGH AT PITTSBURGH (nih funded) |
| Locations | 1 site (PITTSBURGH, UNITED STATES) |
| Trial ID | NIH-11059888 on ClinicalTrials.gov |
What this research studies
This research investigates the effectiveness of administering the BCG vaccine intravenously to macaques infected with the SIV virus, which is similar to HIV in humans. The study aims to understand how this method can provide protection against tuberculosis (TB), a major health threat for individuals with compromised immune systems. By observing the immune response and protection levels in SIV-infected macaques, researchers hope to gather insights that could lead to improved TB prevention strategies for HIV-positive patients. The approach involves comparing the outcomes of SIV-infected macaques receiving the intravenous BCG vaccine to those that do not.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who are HIV-positive and at risk for tuberculosis.
Not a fit: Patients who are not infected with HIV or those who do not have a risk of tuberculosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new method of TB prevention for individuals living with HIV.
How similar studies have performed: Preliminary studies have shown promising results with similar approaches, indicating potential for success in this area.
Where this research is happening
PITTSBURGH, UNITED STATES
- UNIVERSITY OF PITTSBURGH AT PITTSBURGH — PITTSBURGH, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SCANGA, CHARLES A. — UNIVERSITY OF PITTSBURGH AT PITTSBURGH
- Study coordinator: SCANGA, CHARLES A.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acquired Immune Deficiency Syndrome Virus, Acquired Immunodeficiency Syndrome Virus